Literature DB >> 15232714

Simple models improve the discrimination of prostate cancers from the peripheral gland by T1-weighted dynamic MRI.

Fabian Kiessling1, Matthias Lichy, Rainer Grobholz, Melanie Heilmann, Nabeel Farhan, Maurice Stephan Michel, Lutz Trojan, Joerg Ederle, Ulrich Abel, Hans-Ulrich Kauczor, Wolfhard Semmler, Stefan Delorme.   

Abstract

Evaluation of the accuracy of descriptive and physiological parameters calculated from signal intensity-time curves using T1-weighted dynamic contrast enhanced MRI (DCE MRI) to differentiate prostate cancers from the peripheral gland. Twenty-seven patients with prostate cancers were examined with DCE MRI prior radical prostatectomy. Regions of interest were defined in tumors and non-affected areas in the peripheral zone. Dynamic data were parameterized in amplitude and exchange rate constant (kep) using a two-compartment model. Additionally, relative slope during 26, 39, 52 and 65 s, areas under the curve (AUC) and time to start of signal intensity increase (tlag) were determined. Vessel density (VD) of excised prostates was quantified in tumor areas using a CD34 stain. The parameter slope52 showed 20% higher values (P<0.001) in tumors than in the peripheral gland and compared with the other parameters the largest area under the ROC curve (0.81). The minimum total error rate was attained at a cut-point of 0.021, yielding a sample value of sensitivity and specificity of 70% and 88%, respectively, and a bias-corrected sum of sensitivity and specificity of 1.54. In addition, amplitude (P<0.001), kep (P=0.03) and AUC (P<0.001) were significantly higher in tumors. tlag did not discriminate carcinomas from glandular tissue. VD was higher in tumors than in the non-affected peripheral prostate (P=0.05). However, none of the dynamic parameters in carcinomas showed a significant correlation with VD or Gleason score. Although pharmacokinetic modeling in DCE MRI showed potential to discriminate prostate cancers from peripheral prostate tissue, descriptive parameters of the early signal enhancement after contrast media injection reached higher sensitivity and specificity. Copyright 2004 Springer-Verlag

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15232714     DOI: 10.1007/s00330-004-2386-1

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  31 in total

1.  Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging.

Authors:  G Brix; W Semmler; R Port; L R Schad; G Layer; W J Lorenz
Journal:  J Comput Assist Tomogr       Date:  1991 Jul-Aug       Impact factor: 1.826

2.  Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results.

Authors:  G J Jager; E T Ruijter; C A van de Kaa; J J de la Rosette; G O Oosterhof; J R Thornbury; S H Ruijs; J O Barentsz
Journal:  Radiology       Date:  1997-06       Impact factor: 11.105

3.  Pathophysiologic basis of contrast enhancement in breast tumors.

Authors:  M V Knopp; E Weiss; H P Sinn; J Mattern; H Junkermann; J Radeleff; A Magener; G Brix; S Delorme; I Zuna; G van Kaick
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

4.  Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging.

Authors:  R E Port; M V Knopp; U Hoffmann; S Milker-Zabel; G Brix
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

5.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.

Authors:  D F Gleason; G T Mellinger
Journal:  J Urol       Date:  1974-01       Impact factor: 7.450

6.  Prostate cancer staging: should MR imaging be used?--A decision analytic approach.

Authors:  G J Jager; J L Severens; J R Thornbury; J J de La Rosette; S H Ruijs; J O Barentsz
Journal:  Radiology       Date:  2000-05       Impact factor: 11.105

7.  Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging.

Authors:  T M Moehler; H Hawighorst; K Neben; G Egerer; J Hillengass; R Max; A Benner; A D Ho; G van Kaick; H Goldschmidt
Journal:  Int J Cancer       Date:  2001-09       Impact factor: 7.396

8.  The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma.

Authors:  G Brown; D A Macvicar; V Ayton; J E Husband
Journal:  Clin Radiol       Date:  1995-09       Impact factor: 2.350

9.  Prostate cancer: local staging with endorectal surface coil MR imaging.

Authors:  M D Schnall; Y Imai; J Tomaszewski; H M Pollack; R E Lenkinski; H Y Kressel
Journal:  Radiology       Date:  1991-03       Impact factor: 11.105

Review 10.  Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Authors:  P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

View more
  16 in total

Review 1.  Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.

Authors:  Tobias Franiel; Bernd Hamm; Hedvig Hricak
Journal:  Eur Radiol       Date:  2010-12-24       Impact factor: 5.315

Review 2.  Prostate MR imaging at high-field strength: evolution or revolution?

Authors:  Olivier Rouvière; Robert P Hartman; Denis Lyonnet
Journal:  Eur Radiol       Date:  2005-09-10       Impact factor: 5.315

Review 3.  The promise of dynamic contrast-enhanced imaging in radiation therapy.

Authors:  Yue Cao
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

4.  Effect of parallel radiofrequency transmission on arterial input function selection in dynamic contrast-enhanced 3 Tesla pelvic MRI.

Authors:  Hatim Chafi; Saba N Elias; Huyen T Nguyen; Harry T Friel; Michael V Knopp; BeiBei Guo; Steven B Heymsfield; Guang Jia
Journal:  J Magn Reson Imaging       Date:  2015-06-09       Impact factor: 4.813

Review 5.  Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management.

Authors:  Sadhna Verma; Baris Turkbey; Naira Muradyan; Arumugam Rajesh; Francois Cornud; Masoom A Haider; Peter L Choyke; Mukesh Harisinghani
Journal:  AJR Am J Roentgenol       Date:  2012-06       Impact factor: 3.959

6.  The histogram analysis of diffusion-weighted intravoxel incoherent motion (IVIM) imaging for differentiating the gleason grade of prostate cancer.

Authors:  Yu-Dong Zhang; Qing Wang; Chen-Jiang Wu; Xiao-Ning Wang; Jing Zhang; Hui Liu; Xi-Sheng Liu; Hai-Bin Shi
Journal:  Eur Radiol       Date:  2014-11-28       Impact factor: 5.315

7.  Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable?

Authors:  Nicolas Girouin; Florence Mège-Lechevallier; Alejandro Tonina Senes; Alvine Bissery; Muriel Rabilloud; Jean-Marie Maréchal; Marc Colombel; Denis Lyonnet; Olivier Rouvière
Journal:  Eur Radiol       Date:  2006-11-28       Impact factor: 5.315

8.  Impact of stroma on the growth, microcirculation, and metabolism of experimental prostate tumors.

Authors:  Christian M Zechmann; Eva C Woenne; Gunnar Brix; Nicole Radzwill; Martin Ilg; Peter Bachert; Peter Peschke; Stefan Kirsch; Hans-Ulrich Kauczor; Stefan Delorme; Wolfhard Semmler; Fabian Kiessling
Journal:  Neoplasia       Date:  2007-01       Impact factor: 5.715

9.  Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device.

Authors:  K Engelhard; H P Hollenbach; B Kiefer; A Winkel; K Goeb; D Engehausen
Journal:  Eur Radiol       Date:  2006-02-01       Impact factor: 5.315

10.  Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience.

Authors:  M Carlani; S Mancino; E Bonanno; E Finazzi Agrò; G Simonetti
Journal:  Radiol Med       Date:  2008-05-20       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.